AI assistant
Q32 Bio Inc. — Director's Dealing 2018
Apr 4, 2018
34891_dirs_2018-04-04_4a9c5f7b-acdd-4e69-9b24-461b168e778c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-04-02
Reporting Person: Vida Ventures, LLC (10% Owner)
Reporting Person: VV Manager LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-04-02 | Common Stock | C | 395845 | $0.00 | Acquired | 395845 | Indirect |
| 2018-04-02 | Common Stock | P | 375000 | $16.00 | Acquired | 770845 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-04-02 | Series B Preferred Stock | $ | C | 395845 | Disposed | Common Stock (395845) | Indirect |
Footnotes
F1: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein.
F2: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.